—

Novo Nordisk A/S (NVO) — Technical state

As of 2026-11-13 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.

The Closelooknet read

  • Signal: +2.4% at the close — Holding 32.7% off its 52-week high. (as of 2026-11-13)
  • Trend: Novo Nordisk A/S trades 3.8% above its 50-day and 2.9% below its 200-day moving average. (as of 2026-11-13)
  • Index seat: HALO Growth 100

Novo Nordisk researches, manufactures and distributes pharmaceutical products through two units: Obesity and Diabetes Care, and Rare Disease. The first covers diabetes, obesity, cardiovascular and related conditions, including GLP-1 therapies such as Wegovy alongside insulin pens and dosing apps.

The full read — the desk's view, the earnings record, peers and the company snapshot — is on the NVO overview. Research diary readings, not advice.

+2.4% at the close

Holding 32.7% off its 52-week high.

The moving-average stack

FAQ · from the current data · as of 2026-11-13

Quick answers

What is the current Closelooknet signal on NVO?

+2.4% at the close — Holding 32.7% off its 52-week high. As of 2026-11-13; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.

Is NVO above its 50-day and 200-day moving averages?

As of 2026-11-13, Novo Nordisk A/S trades +3.8% above its 50-day and -2.9% below its 200-day average, with the 20-day +4.2% away.

How far is NVO from its 52-week high?

32.7% below the 52-week high and 20.4% above the 52-week low, as of 2026-11-13.

Mentioned on Closelooknet

Where NVO appears in the diary — 1 piece, newest first. Every link is our own writing.

Dailies

Related in the Closelooknet universe

same Closelooknet index seat first, then Drug Manufacturers - General. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.